Key points from article :
Bio-ReCell has announced a new collaboration with French biotech company BIOTEM to enhance two of its key products used in cell therapy—the Atract™ T-cell activation kit and the Neptune™ T-cell separation kit. The partnership brings BIOTEM’s advanced humanized antibodies into Bio-ReCell’s systems, aiming to improve the precision, efficiency, and scalability of T-cell-based therapies.
BIOTEM specializes in the development and production of custom monoclonal antibodies and immunoassays. Their expertise strengthens Bio-ReCell’s mission to deliver reliable and sterile tools for cell therapy manufacturing. By integrating BIOTEM’s antibodies, Bio-ReCell expects to offer more reproducible and high-performing solutions to support the rapidly evolving cell and gene therapy industry.
Dr. Luka Fajs, CEO of Bio-ReCell, emphasized the value of this partnership in improving the performance and consistency of their cell activation and separation technologies. BIOTEM’s CEO/CSO, Dr. Clarence Deffaud, also praised the collaboration, highlighting the innovation and strong results it has already produced.
